Home Clinical trials For patients Ovary RAD-18-003

RAD-18-003

A phase 2, randomised, open label, multicentre study of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are homologous recombination proficient and scheduled to undergo neoadjuvant chemotherapy and interval debulking surgery

Open
Trial drug
Radspherin
Grade
High grade
Prior lines
Frontline
Histology
Serous, Endometrioid
Phase
II

Treatment

This study consists of two different treatment options:

  • Arm A: interval debulking + Radspherin

  • Arm B: interval debulking

You will be randomly allocated to one of the treatment groups on a 2:1 ratio.

Treatment duration

Radspherin is given 2 days after the interval debulking via intraperitoneal in-dwelling catheter placed during surgery. 

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.